WO2022143743A1 - 人lifr抗原结合蛋白及其制备方法和应用 - Google Patents
人lifr抗原结合蛋白及其制备方法和应用 Download PDFInfo
- Publication number
- WO2022143743A1 WO2022143743A1 PCT/CN2021/142404 CN2021142404W WO2022143743A1 WO 2022143743 A1 WO2022143743 A1 WO 2022143743A1 CN 2021142404 W CN2021142404 W CN 2021142404W WO 2022143743 A1 WO2022143743 A1 WO 2022143743A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- antigen
- amino acid
- antibody
- lifr
- Prior art date
Links
- 102000025171 antigen binding proteins Human genes 0.000 title claims abstract description 121
- 108091000831 antigen binding proteins Proteins 0.000 title claims abstract description 121
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 101150071228 Lifr gene Proteins 0.000 title 1
- 101001042362 Homo sapiens Leukemia inhibitory factor receptor Proteins 0.000 claims abstract description 106
- 210000004027 cell Anatomy 0.000 claims abstract description 105
- 102000046686 human LIFR Human genes 0.000 claims abstract description 97
- 238000000034 method Methods 0.000 claims abstract description 56
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 50
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 45
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 29
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 20
- 238000011282 treatment Methods 0.000 claims abstract description 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 120
- 102100021747 Leukemia inhibitory factor receptor Human genes 0.000 claims description 73
- 239000000427 antigen Substances 0.000 claims description 57
- 108091007433 antigens Proteins 0.000 claims description 57
- 102000036639 antigens Human genes 0.000 claims description 57
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 55
- 239000012634 fragment Substances 0.000 claims description 41
- 238000001514 detection method Methods 0.000 claims description 40
- 239000003814 drug Substances 0.000 claims description 36
- 238000006467 substitution reaction Methods 0.000 claims description 33
- 239000013598 vector Substances 0.000 claims description 31
- 241000699670 Mus sp. Species 0.000 claims description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims description 27
- 229940079593 drug Drugs 0.000 claims description 25
- 102000039446 nucleic acids Human genes 0.000 claims description 23
- 108020004707 nucleic acids Proteins 0.000 claims description 23
- 150000007523 nucleic acids Chemical class 0.000 claims description 23
- 239000000611 antibody drug conjugate Substances 0.000 claims description 22
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 22
- 201000010099 disease Diseases 0.000 claims description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
- 210000002865 immune cell Anatomy 0.000 claims description 20
- 150000001413 amino acids Chemical class 0.000 claims description 18
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 16
- 238000007792 addition Methods 0.000 claims description 14
- 238000012217 deletion Methods 0.000 claims description 14
- 230000037430 deletion Effects 0.000 claims description 14
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 12
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 11
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- 201000002528 pancreatic cancer Diseases 0.000 claims description 10
- 230000000903 blocking effect Effects 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 229940124597 therapeutic agent Drugs 0.000 claims description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 8
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 8
- 238000012216 screening Methods 0.000 claims description 8
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 8
- 238000012377 drug delivery Methods 0.000 claims description 7
- 238000000746 purification Methods 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 6
- 208000032612 Glial tumor Diseases 0.000 claims description 6
- 206010018338 Glioma Diseases 0.000 claims description 6
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 6
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 6
- 238000004113 cell culture Methods 0.000 claims description 6
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 206010005003 Bladder cancer Diseases 0.000 claims description 5
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 239000011616 biotin Substances 0.000 claims description 5
- 229960002685 biotin Drugs 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 230000021615 conjugation Effects 0.000 claims description 5
- 206010017758 gastric cancer Diseases 0.000 claims description 5
- 238000001802 infusion Methods 0.000 claims description 5
- 239000003550 marker Substances 0.000 claims description 5
- 201000011549 stomach cancer Diseases 0.000 claims description 5
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 5
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 235000020958 biotin Nutrition 0.000 claims description 4
- 230000001413 cellular effect Effects 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000003053 toxin Substances 0.000 claims description 4
- 231100000765 toxin Toxicity 0.000 claims description 4
- 108700012359 toxins Proteins 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 230000008878 coupling Effects 0.000 claims description 3
- 238000010168 coupling process Methods 0.000 claims description 3
- 238000005859 coupling reaction Methods 0.000 claims description 3
- 229940127089 cytotoxic agent Drugs 0.000 claims description 3
- 239000007850 fluorescent dye Substances 0.000 claims description 3
- 239000003018 immunosuppressive agent Substances 0.000 claims description 3
- 229940125721 immunosuppressive agent Drugs 0.000 claims description 3
- 238000002372 labelling Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000012544 monitoring process Methods 0.000 claims description 3
- 230000003439 radiotherapeutic effect Effects 0.000 claims description 3
- 231100000331 toxic Toxicity 0.000 claims description 3
- 230000002588 toxic effect Effects 0.000 claims description 3
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims description 2
- 238000004451 qualitative analysis Methods 0.000 claims description 2
- 238000004445 quantitative analysis Methods 0.000 claims description 2
- 230000001568 sexual effect Effects 0.000 claims description 2
- 108010083359 Antigen Receptors Proteins 0.000 claims 2
- 102000006306 Antigen Receptors Human genes 0.000 claims 2
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 230000027455 binding Effects 0.000 abstract description 86
- 238000009739 binding Methods 0.000 abstract description 86
- 101710152369 Interleukin-6 receptor subunit beta Proteins 0.000 abstract description 18
- 238000005516 engineering process Methods 0.000 abstract description 13
- 230000002401 inhibitory effect Effects 0.000 abstract description 13
- 238000011830 transgenic mouse model Methods 0.000 abstract description 13
- 230000004614 tumor growth Effects 0.000 abstract description 11
- 241000699660 Mus musculus Species 0.000 abstract description 10
- 230000019491 signal transduction Effects 0.000 abstract description 9
- 108010017324 STAT3 Transcription Factor Proteins 0.000 abstract description 7
- 238000012163 sequencing technique Methods 0.000 abstract description 7
- 238000004458 analytical method Methods 0.000 abstract description 6
- 230000002265 prevention Effects 0.000 abstract description 5
- 230000008827 biological function Effects 0.000 abstract description 4
- 238000010370 cell cloning Methods 0.000 abstract description 3
- 229940125644 antibody drug Drugs 0.000 abstract description 2
- 102000004495 STAT3 Transcription Factor Human genes 0.000 abstract 1
- 230000006798 recombination Effects 0.000 abstract 1
- 238000005215 recombination Methods 0.000 abstract 1
- 101710142062 Leukemia inhibitory factor receptor Proteins 0.000 description 64
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 38
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 38
- 235000018102 proteins Nutrition 0.000 description 38
- 235000001014 amino acid Nutrition 0.000 description 26
- 229940024606 amino acid Drugs 0.000 description 16
- 239000002773 nucleotide Substances 0.000 description 16
- 125000003729 nucleotide group Chemical group 0.000 description 16
- -1 therefore Proteins 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 12
- 230000003285 pharmacodynamic effect Effects 0.000 description 12
- 210000004881 tumor cell Anatomy 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- 241000282693 Cercopithecidae Species 0.000 description 10
- 230000003053 immunization Effects 0.000 description 10
- 108060003951 Immunoglobulin Proteins 0.000 description 9
- 125000000539 amino acid group Chemical group 0.000 description 9
- 238000013401 experimental design Methods 0.000 description 9
- 102000018358 immunoglobulin Human genes 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000002649 immunization Methods 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000011081 inoculation Methods 0.000 description 8
- 210000004180 plasmocyte Anatomy 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000010494 dissociation reaction Methods 0.000 description 7
- 230000005593 dissociations Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 210000004962 mammalian cell Anatomy 0.000 description 6
- 238000010172 mouse model Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 4
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 4
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 238000011729 BALB/c nude mouse Methods 0.000 description 3
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 3
- 229920002449 FKM Polymers 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000599056 Homo sapiens Interleukin-6 receptor subunit beta Proteins 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 3
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 3
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000011577 humanized mouse model Methods 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 229940127121 immunoconjugate Drugs 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 238000012453 sprague-dawley rat model Methods 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- OBYNJKLOYWCXEP-UHFFFAOYSA-N 2-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]-4-isothiocyanatobenzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(N=C=S)=CC=C1C([O-])=O OBYNJKLOYWCXEP-UHFFFAOYSA-N 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 2
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 2
- 239000012623 DNA damaging agent Substances 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000942967 Homo sapiens Leukemia inhibitory factor Proteins 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 108090000630 Oncostatin M Proteins 0.000 description 2
- 241001631646 Papillomaviridae Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 229940122429 Tubulin inhibitor Drugs 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 2
- 210000004507 artificial chromosome Anatomy 0.000 description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000012575 bio-layer interferometry Methods 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229960004926 chlorobutanol Drugs 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 229960002173 citrulline Drugs 0.000 description 2
- 238000007621 cluster analysis Methods 0.000 description 2
- 239000000562 conjugate Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000000066 myeloid cell Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229960003742 phenol Drugs 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000007480 sanger sequencing Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 description 1
- AGGWFDNPHKLBBV-YUMQZZPRSA-N (2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]-5-(carbamoylamino)pentanoic acid Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=O AGGWFDNPHKLBBV-YUMQZZPRSA-N 0.000 description 1
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 102100023698 C-C motif chemokine 17 Human genes 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 1
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102100026662 Delta and Notch-like epidermal growth factor-related receptor Human genes 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 102100022132 High affinity immunoglobulin epsilon receptor subunit gamma Human genes 0.000 description 1
- 108091010847 High affinity immunoglobulin epsilon receptor subunit gamma Proteins 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000978362 Homo sapiens C-C motif chemokine 17 Proteins 0.000 description 1
- 101100021247 Homo sapiens LIF gene Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102000007440 Interleukin-7 Receptor alpha Subunit Human genes 0.000 description 1
- 108010086134 Interleukin-7 Receptor alpha Subunit Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229930126263 Maytansine Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 101000942966 Mus musculus Leukemia inhibitory factor Proteins 0.000 description 1
- 101100021248 Mus musculus Lif gene Proteins 0.000 description 1
- 102000015278 OSM-LIF Receptors Human genes 0.000 description 1
- 108010064527 OSM-LIF Receptors Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000004140 Oncostatin M Human genes 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 101100288143 Rattus norvegicus Klkb1 gene Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108010073443 Ribi adjuvant Proteins 0.000 description 1
- 101150099493 STAT3 gene Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 101000677856 Stenotrophomonas maltophilia (strain K279a) Actin-binding protein Smlt3054 Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 210000000068 Th17 cell Anatomy 0.000 description 1
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 238000012452 Xenomouse strains Methods 0.000 description 1
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000000641 acridinyl group Chemical class C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000037844 advanced solid tumor Diseases 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 108010044540 auristatin Proteins 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229930195731 calicheamicin Natural products 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000013377 clone selection method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000005168 endometrial cell Anatomy 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000000646 extraembryonic cell Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 102000046645 human LIF Human genes 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical group CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 230000005693 optoelectronics Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 229940125415 protein degrader Drugs 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical class C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical class [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- 210000005102 tumor initiating cell Anatomy 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
Description
抗体 | PR301127 | PR301152 | PR301168 | PR301211 | PR300516 | MSC-1 |
KD | - | 1.57E-08 | 4.92E-10 | 4.21E-10 | 3.04E-10 | 1.25E-09 |
抗体 | PR300516 | PR301127 | PR301172 | PR301152 | PR301153 | hIgG1 |
IC50 | 0.562 | NA | NA | 2.018 | 7.382 | 0.001774 |
抗体 | PR301160 | PR301164 | PR301168 | PR301176 | PR301177 | - |
IC50 | 2.404 | 1.129 | 0.991 | 1.436 | 0.496 | - |
抗体 | PR301195 | PR301196 | PR301211 | PR301215 | PR301218 | - |
IC50 | 0.753 | 0.799 | 0.572 | 0.533 | 0.628 | - |
抗体 | PR300516 | MSC-1 |
T1/2(hr) | 178.25 | 212.84 |
Vz(mL/kg) | 114.09 | 81.57 |
AUCall(hr*μg/mL) | 9521.05 | 16003.13 |
Cl(mL/hr/kg) | 0.45 | 0.27 |
C0(μg/mL) | 92.90 | 134.97 |
抗体 | PR300516 | PR301168 |
T1/2(hr) | 219 | 242 |
Vz(mL/kg) | 122 | 177 |
AUCall(hr*μg/mL) | 11056.83 | 8173.60 |
Cl(mL/hr/kg) | 0.40 | 0.53 |
C0(μg/mL) | 92.78 | 65.32 |
组别 | 给药 | TGI(%) |
1 | Isotype,5mg/kg | 0 |
2 | EC359,5mg/kg | 40.99 |
3 | EC359,15mg/kg | 47.85 |
4 | PR300516,5mg/kg | 54.92 |
5 | PR300516,15mg/kg | 55.32 |
6 | MSC-1,5mg/kg | 48.93 |
7 | MSC-1,15mg/kg | 49.34 |
组别 | 给药 | TGI(%) |
1 | Isotype,15mg/kg | 0 |
2 | MSC-1,15mg/kg | 53.96 |
3 | PR300516,15mg/kg | 59.32 |
4 | PR301168,15mg/kg | 59.89 |
组别 | 给药 | TGI(%) |
1 | Isotype,15mg/kg | 0 |
2 | MSC-1,15mg/kg | 39.99 |
3 | PR300516,15mg/kg | 36.35 |
4 | PR301168,15mg/kg | 15.58 |
Claims (31)
- 一种人LIFR抗原结合蛋白,其特征在于,所述的人LIFR抗原结合蛋白包含以下互补决定区:(1)包含SEQ ID NO:1-SEQ ID NO:4中任一个所示的氨基酸序列或其变体序列的重链互补决定区1HCDR1;(2)包含SEQ ID NO:5-SEQ ID NO:15中任一个所示的氨基酸序列或其变体序列的重链互补决定区2HCDR2;(3)包含SEQ ID NO:16-SEQ ID NO:25中任一个所示的氨基酸序列或其变体序列的重链互补决定区3HCDR3;(4)包含SEQ ID NO:26-SEQ ID NO:32中任一个所示的氨基酸序列或其变体序列的轻链互补决定区1LCDR1;(5)包含SEQ ID NO:33-SEQ ID NO:40中任一个所示的氨基酸序列或其变体序列的轻链互补决定区2LCDR2;(6)包含SEQ ID NO:41-SEQ ID NO:45中任一个所示的氨基酸序列或其变体序列的轻链互补决定区3LCDR3;所述变体序列为与其来源的CDR相比具有一个或几个氨基酸的置换、缺失或添加的CDR序列。
- 根据权利要求1所述的人LIFR抗原结合蛋白,其特征在于,所述的人LIFR抗原结合蛋白包含如下互补决定区:(1)包含序列如GFTFSSYGMX 1所示的氨基酸序列或序列如SEQ ID NO:4:GFTFSNYAMT所示的氨基酸序列的重链互补决定区1 HCDR1,其中X 1=H、D或N;和/或(2)包含序列如VIWYDGX 2NKYYX 3DSVKG所示的氨基酸序列、序列如VIWFDGSX 4KYYADSVKG所示的氨基酸序列、序列如SEQ ID NO:7:VIWYDGSNKFYADSVRG所示的氨基酸序列、序列如SEQ ID NO:14:TISGSGAFTYYADAVKG所示的氨基酸序列或序列如SEQ ID NO:15:VISGSGFLTYYADAVKG所示的氨基酸序列的重链互补决定区2 HCDR2,其中X 2=N或S,X 3=E、A或T,X 4=N、I、L或V;和/或(3)包含序列如SEQ ID NO:16:DGESSMVRGLLNWFDP所示的氨基酸序列、序列如SEQ ID NO:17:ELRYFDWLLSPFDY所示的氨基酸序列、序列如SEQ IDNO:21:GERTLDL所示的氨基酸序列、序列如ELWFGELLSPX 5DF所示的氨基酸序列、序列如GQLVX 6DX 7所示的氨基酸序列或序列如GGILTGFDX 8所示的氨基酸序列的重链互补决定区3HCDR3,其中X 5=L或F,X 6=G或Q,X 7=Y、F或L,X 8=N或Y;和/或(4)包含序列如RASQSX 9SSSX 10LA所示的氨基酸序列、序列如RASQSISSX 11LX 12所示的氨基酸序列或序列如SEQ ID NO:32:RASQNLNSNLA所示的氨基酸序列的轻链互补决定区1LCDR1,其中X 9=V或I,X 10=Y或F,X 11=Y、W或N,X 12=N或A;和/或(5)包含序列如GX 13SSRAT所示的氨基酸序列、序列如KASX 14LEX 15所示的氨基酸序列、序列如SEQ ID NO:35:AASNRAT所示的氨基酸序列、序列如SEQ ID NO:36:AASSLQS所示的氨基酸序列或序列如SEQ ID NO:40:GASTRAP所示的氨基酸序列的轻链互补决定区2LCDR2,其中X 13=A或T,X 14=S或N,X 15=S或N;和/或(6)包含序列如SEQ ID NO:41:QQYGSSPFT所示的氨基酸序列、序列如SEQ ID NO:42:QQSYSTPLT所示的氨基酸序列、序列如SEQ ID NO:43:QQYKSFSPGGLT所示的氨基酸序列、序列如SEQ ID NO:44:QQYKSNPLT所示的氨基酸序列或序列如SEQ ID NO:45:QQYNNWPRT所示的氨基酸序列的轻链互补决定区3 LCDR3。
- 根据权利要求2所述的人LIFR抗原结合蛋白,其特征在于,所述的人LIFR抗原结合蛋白包含:(1)、包含SEQ ID NO:46-SEQ ID NO:59中任一个所示的氨基酸序列的重链可变区VH;和/或包含SEQ ID NO:60-SEQ ID NO:69中任一个所示的氨基酸序列的轻链可变区VL;或者(2)、与(1)中的任一VH相比具有至少70%、至少80%、至少85%、至少90%、至少91%、至少92%、至少93%、至少94%、至少95%、至少96%、至少97%、至少98%或至少99%的序列同一性的VH;和/或,与(1)中的任一VL相比具有至少70%、至少80%、至少85%、至少90%、至少91%、至少92%、至少93%、至少94%、至少95%、至少96%、至少97%、至少98%或至少99%的序列同一性的VL;或者(3)、与(1)中的任一VH相比具有一个或几个氨基酸的置换、缺失或添 加或其任意组合的VH;和/或,与(1)中的任一VL相比具有一个或几个氨基酸的置换、缺失或添加或其任意组合的VL;所述的置换是保守置换。
- 根据权利要求3所述的人LIFR抗原结合蛋白,其特征在于,所述的人LIFR抗原结合蛋白包含:(1)包含SEQ ID NO:70-SEQ ID NO:83中任一个所示的氨基酸序列的重链HC;和/或包含SEQ ID NO:84-SEQ ID NO:93中任一个所示的氨基酸序列的轻链LC;或者(2)重链和轻链,其中,与(1)中的重链和轻链相比,所述重链具有至少80%、至少85%、至少90%、至少91%、至少92%、至少93%、至少94%、至少95%、至少96%、至少97%、至少98%或至少99%的序列同一性;和/或,所述轻链具有至少70%、至少80%、至少85%、至少90%、至少91%、至少92%、至少93%、至少94%、至少95%、至少96%、至少97%、至少98%或至少99%的序列同一性。
- 根据权利要求1-4任意一项所述的人LIFR抗原结合蛋白,其特征在于,所述的人LIFR抗原结合蛋白包含:(1)如SEQ ID NO:1所示的HCDR1,如SEQ ID NO:5所示的HCDR2,如SEQ ID NO:16所示的HCDR3,和/或如SEQ ID NO:26所示的LCDR1,如SEQ ID NO:33所示的LCDR2,如SEQ ID NO:41所示的LCDR3;和/或(2)如SEQ ID NO:2所示的HCDR1,如SEQ ID NO:7所示的HCDR2,如SEQ ID NO:18所示的HCDR3,和/或如SEQ ID NO:26所示的LCDR1,如SEQ ID NO:33所示的LCDR2,如SEQ ID NO:41所示的LCDR3;和/或(3)如SEQ ID NO:1所示的HCDR1,如SEQ ID NO:6所示的HCDR2,如SEQ ID NO:17所示的HCDR3,和/或如SEQ ID NO:27所示的LCDR1,如SEQ ID NO:34所示的LCDR2,如SEQ ID NO:41所示的LCDR3;和/或(4)如SEQ ID NO:2所示的HCDR1,如SEQ ID NO:7所示的HCDR2,如SEQ ID NO:19所示的HCDR3,和/或如SEQ ID NO:26所示的LCDR1,如SEQ ID NO:33所示的LCDR2,如SEQ ID NO:41所示的LCDR3;和/或(5)如SEQ ID NO:1所示的HCDR1,如SEQ ID NO:12所示的HCDR2,如SEQ ID NO:23所示的HCDR3,和/或如SEQ ID NO:30所示的LCDR1,如SEQ ID NO:38所示的LCDR2,如SEQ ID NO:44所示的LCDR3;和/或(6)如SEQ ID NO:1所示的HCDR1,如SEQ ID NO:10所示的HCDR2,如SEQ ID NO:20所示的HCDR3,和/或如SEQ ID NO:29所示的LCDR1,如SEQ ID NO:36所示的LCDR2,如SEQ ID NO:42所示的LCDR3;和/或(7)如SEQ ID NO:3所示的HCDR1,如SEQ ID NO:10所示的HCDR2,如SEQ ID NO:21所示的HCDR3,和/或如SEQ ID NO:30所示的LCDR1,如SEQ ID NO:37所示的LCDR2,如SEQ ID NO:43所示的LCDR3;和/或(8)如SEQ ID NO:3所示的HCDR1,如SEQ ID NO:11所示的HCDR2,如SEQ ID NO:22所示的HCDR3,和/或如SEQ ID NO:30所示的LCDR1,如SEQ ID NO:38所示的LCDR2,如SEQ ID NO:44所示的LCDR3;和/或(9)如SEQ ID NO:3所示的HCDR1,如SEQ ID NO:11所示的HCDR2,如SEQ ID NO:22所示的HCDR3,和/或如SEQ ID NO:30所示的LCDR1,如SEQ ID NO:39所示的LCDR2,如SEQ ID NO:44所示的LCDR3;和/或(10)如SEQ ID NO:1所示的HCDR1,如SEQ ID NO:11所示的HCDR2,如SEQ ID NO:22所示的HCDR3,和/或如SEQ ID NO:30所示的LCDR1,如SEQ ID NO:38所示的LCDR2,如SEQ ID NO:44所示的LCDR3;和/或(11)如SEQ ID NO:1所示的HCDR1,如SEQ ID NO:13所示的HCDR2,如SEQ ID NO:22所示的HCDR3,和/或如SEQ ID NO:30所示的LCDR1,如SEQ ID NO:38所示的LCDR2,如SEQ ID NO:44所示的LCDR3。
- 根据权利要求5所述的人LIFR抗原结合蛋白,其特征在于,所述的人LIFR抗原结合蛋白包含:(1)如SEQ ID NO:46所示的VH,和/或如SEQ ID NO:60所示的VL;(2)如SEQ ID NO:48所示的VH,和/或如SEQ ID NO:62所示的VL;(3)如SEQ ID NO:47所示的VH,和/或如SEQ ID NO:61所示的VL;(4)如SEQ ID NO:49所示的VH,和/或如SEQ ID NO:62所示的VL;(5)如SEQ ID NO:55所示的VH,和/或如SEQ ID NO:67所示的VL;(6)如SEQ ID NO:52所示的VH,和/或如SEQ ID NO:65所示的VL;(7)如SEQ ID NO:53所示的VH,和/或如SEQ ID NO:66所示的VL;(8)如SEQ ID NO:54所示的VH,和/或如SEQ ID NO:67所示的VL;(9)如SEQ ID NO:54所示的VH,和/或如SEQ ID NO:68所示的VL;(10)如SEQ ID NO:56所示的VH,和/或如SEQ ID NO:67所示的VL;(11)如SEQ ID NO:57所示的VH,和/或如SEQ ID NO:67所示的VL;或者,与(1)-(11)中的任一VH相比具有至少70%、至少80%、至少85%、至少90%、至少91%、至少92%、至少93%、至少94%、至少95%、至少96%、至少97%、至少98%或至少99%的序列同一性的VH;和/或,与(1)-(11)中的任一VL相比具有至少70%、至少80%、至少85%、至少90%、至少91%、至少92%、至少93%、至少94%、至少95%、至少96%、至少97%、至少98%或至少99%的序列同一性的VL;或者,与(1)-(11)中的任一VH相比具有一个或几个氨基酸的置换、缺失或添加或其任意组合的VH;和/或,与(1)-(11)中的任一VL相比具有一个或几个氨基酸的置换、缺失或添加或其任意组合的VL;所述的置换是保守置换。
- 根据权利要求6所述的人LIFR抗原结合蛋白,其特征在于,所述的人LIFR抗原结合蛋白包含:(1)如SEQ ID NO:70所示的HC,和/或如SEQ ID NO:84所示的LC;(2)如SEQ ID NO:72所示的HC,和/或如SEQ ID NO:86所示的LC;(3)如SEQ ID NO:71所示的HC,和/或如SEQ ID NO:85所示的LC;(4)如SEQ ID NO:73所示的HC,和/或如SEQ ID NO:86所示的LC;(5)如SEQ ID NO:79所示的HC,和/或如SEQ ID NO:91所示的LC;(6)如SEQ ID NO:76所示的HC,和/或如SEQ ID NO:89所示的LC;(7)如SEQ ID NO:77所示的HC,和/或如SEQ ID NO:90所示的LC;(8)如SEQ ID NO:78所示的HC,和/或如SEQ ID NO:91所示的LC;(9)如SEQ ID NO:78所示的HC,和/或如SEQ ID NO:92所示的LC;(10)如SEQ ID NO:80所示的HC,和/或如SEQ ID NO:91所示的LC;(11)如SEQ ID NO:81所示的HC,和/或如SEQ ID NO:91所示的LC;或者,与(1)-(11)中的重链和轻链相比,所述重链具有至少80%、至少85%、至少90%、至少91%、至少92%、至少93%、至少94%、至少95%、至少96%、至少97%、至少98%或至少99%的序列同一性;和/或,所述轻链具有至少70%、至少80%、至少85%、至少90%、至少91%、至少92%、至少93%、至少94%、至少95%、至少96%、至少97%、至少98%或至少99%的序列同一性。
- 根据权利要求1-7任意一项所述的人LIFR抗原结合蛋白,其特征在于,所述 的人LIFR抗原结合蛋白包括嵌合抗体、人源化抗体或全人源抗体。
- 根据权利要求1-8任意一项所述的人LIFR抗原结合蛋白,其特征在于,所述的人LIFR抗原结合蛋白包括全长抗体、Fab、Fab’、F(ab’)2、Fv、scFv、di-scFv、双特异性抗体、多特异性抗体、重链抗体和/或单域抗体,或由上述抗体制得的单克隆抗体和/或多克隆抗体。
- 编码权利要求1-9任意一项所述的人LIFR抗原结合蛋白的核酸分子。
- 包含权利要求10所述的核酸分子的载体。
- 包含权利要求10所述的核酸分子或权利要求11所述的载体的宿主细胞。
- 一种嵌合抗原受体,其特征在于,所述的嵌合抗原受体包含权利要求1-9中任意一项所述的人LIFR抗原结合蛋白。
- 一种免疫细胞,其特征在于,所述的免疫细胞包含权利要求13所述的嵌合抗原受体。
- 一种抗原结合蛋白衍生物,其特征在于,所述的抗原结合蛋白衍生物包含权利要求1-9任意一项所述的人LIFR抗原结合蛋白和可检测的标记分子,所述的可检测的标记分子为酶、放射性核素、荧光染料、发光物质或生物素。
- 一种多特异性抗体,其特征在于,所述的多特异性抗体包含权利要求1-9任一项所述的人LIFR抗原结合蛋白,和另外的抗体或其片段或抗体类似物;所述多特异性抗体是双特异性抗体或三特异性抗体或四特异性抗体。
- 一种抗体药物偶联物,其特征在于,所述的抗体药物偶联物包括抗体部分和偶联部分,所述抗体部分包含权利要求1-9任意一项所述的人LIFR抗原结合蛋白,所述偶联部分包括但不限于可检测标记物、药物、毒素、细胞因子、放射性核素、酶、或其组合,所述抗体部分和偶联部分通过化学键或接头进行偶联。
- 一种药物组合物,其特征在于,所述的药物组合物包含权利要求1-9任意一项所述的人LIFR抗原结合蛋白、权利要求10所述的核酸分子、权利要求11所述的载体、权利要求12所述的宿主细胞、权利要求14所述的免疫细胞、权利要求15所述的抗原结合蛋白衍生物、权利要求16所述的多特异性抗体和/或权利要求17所述的抗体药物偶联物及任选地药学上可接受的载体。
- 根据权利要求18所述的药物组合物,其特征在于,所述的药物组合物还包含组合治疗剂,所述的组合治疗剂包括但不限于化学治疗剂、放射治疗剂、免疫抑制剂、细胞毒性药物。
- 权利要求1-9任意一项所述的人LIFR抗原结合蛋白的生产方法,其特征在于,所述的方法包括在使得权利要求1-9任一项所述的抗原结合蛋白表达的情况下,培养权利要求12所述的宿主细胞。
- 根据权利要求20所述的人LIFR抗原结合蛋白的方法,其特征在于,所述的方法包括以下步骤:(1)采用LIFR-ECD蛋白作为抗原免疫小鼠;(2)筛选分泌抗体的抗原特异性B细胞;(3)从步骤(2)筛选出的单个B细胞中恢复抗体的重链和轻链序列;(4)将步骤(3)恢复的抗体重链和轻链引入宿主细胞,经细胞培养、纯化制备得到人LIFR抗原结合蛋白。
- 权利要求1-9任意一项所述的人LIFR抗原结合蛋白、权利要求10所述的核酸分子、权利要求11所述的载体、权利要求12所述的宿主细胞、权利要求13所述的嵌合抗原受体、权利要求14所述的免疫细胞、权利要求15所述的抗原结合蛋白衍生物、权利要求16所述的多特异性抗体、权利要求17所述的抗体药物偶联物和/或权利要求18-19所述的药物组合物在制备用于LIF和/或LIFR阻断药物、试剂盒和/或医疗装置中的应用。
- 权利要求1-9任意一项所述的人LIFR抗原结合蛋白、权利要求11所述的核酸分子、权利要求12所述的载体、权利要求13所述的宿主细胞、权利要求14所述的嵌合抗原受体、权利要求15所述的免疫细胞、权利要求16所述的抗原结合蛋白衍生物、权利要求17所述的多特异性抗体、权利要求18所述的抗体药物偶联物和/或权利要求19-20所述的药物组合物在制备用于预防和/或治疗LIFR阳性疾病的药物、试剂盒和/或给药装置中的应用。
- 权利要求1-9任意一项所述的人LIFR抗原结合蛋白、权利要求15所述的抗原结合蛋白衍生物在制备LIFR检测试剂或试剂盒中的用途。
- LIFR检测方法,其特征在于,利用权利要求1-9任意一项所述的人LIFR抗原结合蛋白定性或定量分析检测LIFR,所述的检测方法用于非疾病诊断或治疗目的。
- LIFR阳性相关疾病的治疗方法,其特征在于,所述的方法为向有需要的受试者施用有效量的权利要求1-9任意一项所述的人LIFR抗原结合蛋白、权利要求14所述的免疫细胞、权利要求15所述的抗原结合蛋白衍生物、权利要求16所述的多特异性抗体,权利要求17所述的抗体药物偶联物和/或权利要求18-19所述的药物组合物。
- 根据权利要求23所述的应用或权利要求26所述的方法,其特征在于,所述LIFR阳性疾病为肿瘤,所述肿瘤包括但不限于胆管癌、结直肠癌、神经胶质瘤、前列腺癌、卵巢癌、胃癌、鼻咽癌、乳腺癌、膀胱癌、胰腺癌和非小细胞肺癌。
- 试剂盒,其特征在于,所述的试剂盒包括权利要求1-9任意一项所述的人LIFR抗原结合蛋白、权利要求10所述的核酸分子、权利要求11所述的载体、权利要求12所述的宿主细胞、权利要求13所述的嵌合抗原受体、权利要求14所述的免疫细胞、权利要求15所述的抗原结合蛋白衍生物、权利要求16所述的多特异性抗体、权利要求17所述的抗体药物偶联物和/或权利要求18-19所述的药物组合物,及任选地,说明书。
- 给药装置,其特征在于,所述的给药装置包含:(1)用于对有需要的受试者施用权利要求18或19所述的药物组合物的输注模块,以及(2)任选的药效监控模块。
- LIFR抗原结合蛋白在制备癌症治疗药物中的用途,其特征在于,所述癌症选自胆管癌、结直肠癌、神经胶质瘤、前列腺癌、卵巢癌、胃癌、鼻咽癌、乳腺癌、膀胱癌、胰腺癌和非小细胞肺癌。
- 根据权利要求30所述的用途,其特征在于,所述LIFR抗原结合蛋白如权利要求1-9任一项所述。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2021414160A AU2021414160A1 (en) | 2020-12-31 | 2021-12-29 | Human lifr antigen binding protein, preparation method therefor, and application thereof |
JP2023540785A JP2024501739A (ja) | 2020-12-31 | 2021-12-29 | ヒトlifr抗原結合タンパク質、その製造方法及び応用 |
KR1020237025486A KR20230125037A (ko) | 2020-12-31 | 2021-12-29 | 인간 lifr 항원 결합 단백질, 이의 제조 방법, 및 이의응용 |
CA3203886A CA3203886A1 (en) | 2020-12-31 | 2021-12-29 | Human lifr antigen binding protein, preparation method therefor, and application thereof |
CN202180088318.8A CN117043189A (zh) | 2020-12-31 | 2021-12-29 | 人lifr抗原结合蛋白及其制备方法和应用 |
EP21914475.5A EP4253413A1 (en) | 2020-12-31 | 2021-12-29 | Human lifr antigen binding protein, preparation method therefor, and application thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011619032.1 | 2020-12-31 | ||
CN202011619032 | 2020-12-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022143743A1 true WO2022143743A1 (zh) | 2022-07-07 |
Family
ID=82260235
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/142404 WO2022143743A1 (zh) | 2020-12-31 | 2021-12-29 | 人lifr抗原结合蛋白及其制备方法和应用 |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP4253413A1 (zh) |
JP (1) | JP2024501739A (zh) |
KR (1) | KR20230125037A (zh) |
CN (1) | CN117043189A (zh) |
AU (1) | AU2021414160A1 (zh) |
CA (1) | CA3203886A1 (zh) |
TW (1) | TW202227502A (zh) |
WO (1) | WO2022143743A1 (zh) |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3850752A (en) | 1970-11-10 | 1974-11-26 | Akzona Inc | Process for the demonstration and determination of low molecular compounds and of proteins capable of binding these compounds specifically |
US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
WO2002043478A2 (en) | 2000-11-30 | 2002-06-06 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
CN104341529A (zh) | 2013-07-26 | 2015-02-11 | 三星电子株式会社 | 带有DARPin的双特异性嵌合蛋白 |
WO2015141862A1 (en) | 2014-03-17 | 2015-09-24 | Mitsubishi Tanabe Pharma Corporation | Antibody-fynomer conjugates |
CN111378036A (zh) | 2020-01-09 | 2020-07-07 | 湖北医药学院 | 一种抗人白血病抑制因子单克隆抗体的制备方法及其应用 |
CN111868086A (zh) | 2016-12-19 | 2020-10-30 | 马赛克生物医学一人有限责任公司 | 抗lif抗体及其用途 |
-
2021
- 2021-12-29 WO PCT/CN2021/142404 patent/WO2022143743A1/zh active Application Filing
- 2021-12-29 CN CN202180088318.8A patent/CN117043189A/zh active Pending
- 2021-12-29 CA CA3203886A patent/CA3203886A1/en active Pending
- 2021-12-29 TW TW110149458A patent/TW202227502A/zh unknown
- 2021-12-29 AU AU2021414160A patent/AU2021414160A1/en active Pending
- 2021-12-29 KR KR1020237025486A patent/KR20230125037A/ko active Search and Examination
- 2021-12-29 EP EP21914475.5A patent/EP4253413A1/en active Pending
- 2021-12-29 JP JP2023540785A patent/JP2024501739A/ja active Pending
Patent Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3850752A (en) | 1970-11-10 | 1974-11-26 | Akzona Inc | Process for the demonstration and determination of low molecular compounds and of proteins capable of binding these compounds specifically |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
US4366241B1 (zh) | 1980-08-07 | 1988-10-18 | ||
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5585089A (en) | 1988-12-28 | 1996-12-17 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5693762A (en) | 1988-12-28 | 1997-12-02 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US6180370B1 (en) | 1988-12-28 | 2001-01-30 | Protein Design Labs, Inc. | Humanized immunoglobulins and methods of making the same |
WO2002043478A2 (en) | 2000-11-30 | 2002-06-06 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
CN104341529A (zh) | 2013-07-26 | 2015-02-11 | 三星电子株式会社 | 带有DARPin的双特异性嵌合蛋白 |
WO2015141862A1 (en) | 2014-03-17 | 2015-09-24 | Mitsubishi Tanabe Pharma Corporation | Antibody-fynomer conjugates |
CN111868086A (zh) | 2016-12-19 | 2020-10-30 | 马赛克生物医学一人有限责任公司 | 抗lif抗体及其用途 |
CN111378036A (zh) | 2020-01-09 | 2020-07-07 | 湖北医药学院 | 一种抗人白血病抑制因子单克隆抗体的制备方法及其应用 |
Non-Patent Citations (33)
Title |
---|
"Antibody Engineering: Methods and Protocols", vol. 248, 2004, HUMANA PRESS |
"GenBank", Database accession no. NP_001121143.1 |
BRUGGERMANN ET AL., YEAR IN IMMUNOLOGY, vol. 7, 1993, pages 33 |
BRUMMELL ET AL., BIOCHEM., vol. 32, 1993, pages 1180 - 1187 |
BURKS ET AL., PROC. NATL ACAD. SET USA, vol. 94, 1997, pages 412 - 417 |
CHOTHIA ET AL., NATURE, vol. 342, 1989, pages 878 - 883 |
CHOTHIALESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917 |
DATABASE Protein 1 December 2020 (2020-12-01), "Chain L, Antibody Fab fragment light chain", XP055950799, retrieved from NCBI Database accession no. 6MVL_L * |
DATABASE Protein 1 December 2020 (2020-12-01), "IGH c2032_heavy_IGHV3-33_IGHD3-10_IGHJ4, partial [Homo sapiens] - - ", XP055950909, retrieved from NCBI Database accession no. QEP16307 * |
DATABASE Protein 18 February 1997 (1997-02-18), "immunoglobulin heavy chain variable region, partial [Homo sapiens] - - ", XP055950829, retrieved from NCBI Database accession no. AAC51020 * |
DATABASE Protein 18 February 1997 (1997-02-18), "immunoglobulin heavy chain variable region, partial [Homo sapiens] ", XP055950844, retrieved from NCBI Database accession no. AAC51023 * |
DATABASE Protein 19 October 2015 (2015-10-19), "1-732 antibody light chain variable region, partial [synthetic constru ]", XP055950839, retrieved from NCBI Database accession no. ALJ30113 * |
DATABASE Protein 24 July 2016 (2016-07-24), "immunoglobulin kappa light chain, partial [Homo sapiens] ", XP055950798, retrieved from NCBI Database accession no. BAH04687 * |
DATABASE Protein 25 July 2016 (2016-07-25), "immunoglobulin heavy chain variable region, partial [Homo sapiens] ", XP055950842, retrieved from NCBI Database accession no. AAC18328 * |
DATABASE Protein 26 July 2016 (2016-07-26), "immunoglobulin heavy chain variable region EM2-PPS-4-VH3-4, partial [H ", XP055950816, retrieved from NCBI Database accession no. ABC66902 * |
DATABASE Protein 26 July 2016 (2016-07-26), "immunoglobulin heavy chain, partial [Homo sapiens]", XP055950913, retrieved from NCBI Database accession no. AAS68225 * |
DATABASE Protein 26 July 2016 (2016-07-26), "immunoglobulin kappa light chain variable region, partial [Homo sapien", XP055950837, retrieved from NCBI Database accession no. AAZ09096 * |
DUCHOSAL ET AL., NATURE, vol. 355, 1992, pages 258 |
HARDING, F.LONBERG, N., ANN. NYACAD. SCI., vol. 764, 1995, pages 536 - 546 |
HOOGENBOOM ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581 - 597 |
HUSZAR, D., INTERN. REV. IMMUNOL., vol. 13, 1995, pages 65 - 93 |
ILJPAC-ILJB COMMITTEE, J. BIOOL. CHEM, vol. 243, 1968, pages 3558 |
JAKOBOVITS ET AL., NATURE, vol. 362, 1993, pages 255 - 258 |
JAKOBOVITS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 2551 |
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, NATIONAL INSTITUTES OF HEALTH |
KOBAYASHI ET AL., PROTEIN ENG, vol. 12, no. 10, 1999, pages 879 - 884 |
LEFRANC ET AL., DEV. COMPARAT. IMMUNOL., vol. 27, 2003, pages 55 - 77 |
LONBERG ET AL., NATURE, vol. 368, no. 6474, 1994, pages 856 - 859 |
MARTIN ACRCHEETHAM JCREES AR: "Modelling antibody hypervariable loops: A combined algorithm", PROC NATL ACAD SCI USA, vol. 86, 1989, pages 9268 - 9272, XP000165667, DOI: 10.1073/pnas.86.23.9268 |
VAUGHAN ET AL., NATURE BIOTECH, vol. 14, 1996, pages 309 |
VISWANADHAPALLI SURYAVATHI, LUO YILIAO, SAREDDY GANGADHARA R., SANTHAMMA BINDU, ZHOU MEI, LI MENGXING, MA SHIHONG, SONAVANE RAJNI,: "EC359: A First-in-Class Small-Molecule Inhibitor for Targeting Oncogenic LIFR Signaling in Triple-Negative Breast Cancer", MOLECULAR CANCER THERAPEUTICS, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 18, no. 8, 1 August 2019 (2019-08-01), US , pages 1341 - 1354, XP055950580, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-18-1258 * |
WU, H. X. ET AL.: "LIFR promotes tumor angiogenesis by up-regulating IL-8 levels in colorectal cancer.", BIOCHIMICA ET BIOPHYSICA ACTA (BBA)-MOLECULAR BASIS OF DISEASE., vol. 1864, no. 9, 9 May 2018 (2018-05-09), XP085428762, DOI: 10.1016/j.bbadis.2018.05.004 * |
ZHAO FENGQING, CHEN SHUAI, XING DAN: "Expressions of LIFR and MMP-12 in Gallbladder Carcinoma and Its Clinical Significance", JOURNAL OF CLINICAL AND PATHOLOGICAL RESEARCH, 314000, vol. 38, no. 8, 31 December 2018 (2018-12-31), pages 1601 - 1607, XP055950600, ISSN: 2095-6959, DOI: 10.3978/j.issn.2095-6959.2018.08.002 * |
Also Published As
Publication number | Publication date |
---|---|
CA3203886A1 (en) | 2022-07-07 |
AU2021414160A9 (en) | 2024-05-09 |
CN117043189A (zh) | 2023-11-10 |
JP2024501739A (ja) | 2024-01-15 |
TW202227502A (zh) | 2022-07-16 |
AU2021414160A1 (en) | 2023-07-20 |
KR20230125037A (ko) | 2023-08-28 |
EP4253413A1 (en) | 2023-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6924360B2 (en) | Antibodies against the MUC18 antigen | |
US7067131B2 (en) | Methods for using anti-MUC18 antibodies | |
WO2020082209A1 (zh) | 抗cldn18.2抗体及其用途 | |
ES2656446T3 (es) | Anticuerpos anti-VEGF y sus usos | |
US7090844B2 (en) | Use of antibodies against the MUC18 antigen | |
ES2639056T3 (es) | Anticuerpos anti-EGFR y sus usos | |
JP2021531826A (ja) | 栄養膜細胞表面抗原2(trop2)に対する特異的な抗体 | |
JP2005538682A (ja) | カルボキシックアンヒドラーゼix(caix)腫瘍抗原に対する抗体 | |
US11965037B2 (en) | Anti-HER3 humanized monoclonal antibody | |
WO2022068810A1 (zh) | 抗Claudin18.2和CD3的双特异性抗体以及其用途 | |
JP2022514693A (ja) | Muc18に特異的な抗体 | |
CN115812081A (zh) | 抗ctla-4抗体及其用途 | |
CN113045659B (zh) | 抗cd73人源化抗体 | |
WO2020156439A1 (zh) | 抗cd79b抗体、其抗原结合片段及其医药用途 | |
WO2024012539A1 (zh) | 抗Nectin-4抗体及其应用 | |
WO2023174029A1 (zh) | 一种prlr抗原结合蛋白及其制备方法和应用 | |
JP2022514786A (ja) | Muc18に特異的な抗体 | |
WO2022143743A1 (zh) | 人lifr抗原结合蛋白及其制备方法和应用 | |
US20240117034A1 (en) | GARP Protein Antibody and Use Thereof | |
CN111303288A (zh) | 一种分离的结合抗原psma的蛋白及其用途 | |
WO2022068809A1 (zh) | 抗cd3抗体以及其用途 | |
WO2024007671A1 (zh) | 特异性结合cd24的抗体及其用途 | |
US20240124576A1 (en) | Preparation of siglec-15 binding protein and use thereof | |
TW202140551A (zh) | 抗cldn18.2抗體及其用途 | |
CN113321730A (zh) | Cldn18.2抗体及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21914475 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180088318.8 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 3203886 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023540785 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2021914475 Country of ref document: EP Effective date: 20230630 |
|
ENP | Entry into the national phase |
Ref document number: 2021414160 Country of ref document: AU Date of ref document: 20211229 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20237025486 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |